GO
Loading...

Life Sciences

More

  • Hyperion tops Street 4Q forecasts Thursday, 26 Feb 2015 | 7:51 PM ET

    BRISBANE, Calif. _ Hyperion Therapeutics Inc. on Thursday reported fourth-quarter earnings of $7.1 million. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share. Analysts expected $24.9 million, according to Zacks.

  • Aegerion reports 4Q loss Thursday, 26 Feb 2015 | 7:48 PM ET

    CAMBRIDGE, Mass. _ Aegerion Pharmaceuticals Inc. on Thursday reported a loss of $8.1 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 5 cents per share. Analysts expected $49.2 million, according to Zacks.

  • Raptor Pharmaceutical reports 4Q loss Thursday, 26 Feb 2015 | 7:31 PM ET

    NOVATO, Calif. _ Raptor Pharmaceutical Corp. on Thursday reported a loss of $18.9 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share. Raptor Pharmaceutical shares have decreased slightly more than 8 percent since the beginning of the year.

  • Synageva BioPharma reports 4Q loss Thursday, 26 Feb 2015 | 7:24 PM ET

    LEXINGTON, Mass. _ Synageva BioPharma Corp. on Thursday reported a loss of $57.7 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of $1.69 per share. Synageva BioPharma shares have climbed 7 percent since the beginning of the year.

  • NewLink beats 4Q profit forecasts Thursday, 26 Feb 2015 | 10:48 AM ET

    AMES, Iowa _ NewLink Genetics Corp. on Thursday reported fourth-quarter net income of $126.9 million, after reporting a loss in the same period a year earlier. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 78 cents per share. Analysts expected $3.9 million, according to Zacks.

  • Merrimack reports 4Q loss Thursday, 26 Feb 2015 | 10:13 AM ET

    CAMBRIDGE, Mass. _ Merrimack Pharmaceuticals Inc. on Thursday reported a loss of $9.7 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share. Analysts expected $25.1 million, according to Zacks.

  • Sarepta Therapeutics reports 4Q loss Thursday, 26 Feb 2015 | 7:57 AM ET

    CAMBRIDGE, Mass. _ Sarepta Therapeutics Inc. on Thursday reported a loss of $44.4 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 83 cents per share. Sarepta Therapeutics shares have increased roughly 4 percent since the beginning of the year.

  • Bayer is 'focusing on life sciences'  Thursday, 26 Feb 2015 | 6:00 AM ET

    Marijn Dekkers, CEO of Bayer, talks about the company's plans to separate themselves from their material science unit, saying they will focus on life sciences businesses going forward.

  • Medivation beats Street 4Q forecasts Wednesday, 25 Feb 2015 | 7:15 PM ET

    SAN FRANCISCO _ Medivation Inc. on Wednesday reported fourth-quarter profit of $164.2 million. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $1.21 per share. Medivation shares have risen 14 percent since the beginning of the year.

  • Nektar reports 4Q loss Tuesday, 24 Feb 2015 | 7:42 PM ET

    SAN FRANCISCO _ Nektar Therapeutics on Tuesday reported a loss of $45.7 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 37 cents per share. Analysts expected $15 million, according to Zacks.

  • Vivus reports 4Q loss Tuesday, 24 Feb 2015 | 5:12 PM ET

    MOUNTAIN VIEW, Calif. _ Vivus Inc. on Tuesday reported a loss of $25.4 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share. Analysts expected $23.2 million, according to Zacks.

  • Dyax reports 4Q loss Tuesday, 24 Feb 2015 | 11:58 AM ET

    BURLINGTON, Mass. _ Dyax Corp. on Tuesday reported a loss of $2.3 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 4 cents per share. Dyax shares have climbed 17 percent since the beginning of the year.

  • Celldex reports 4Q loss Tuesday, 24 Feb 2015 | 11:58 AM ET

    HAMPTON, N.J. _ Celldex Therapeutics Inc. on Tuesday reported a loss of $31.8 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 35 cents per share. Analysts expected $338,000, according to Zacks.

  • NEW YORK— Bristol-Myers Squibb is using an acquisition that could be worth more than $1 billion and a separate collaboration agreement to continue its push into developing cancer treatments that use a patient's immune system to attack the disease. The New York drugmaker said Monday that it will buy the privately held biotechnology company Flexus for $800...

  • Ariad reports 4Q loss Thursday, 19 Feb 2015 | 8:42 AM ET

    CAMBRIDGE, Mass. _ Ariad Pharmaceuticals Inc. on Thursday reported a loss of $5.8 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share. Analysts expected $47 million, according to Zacks.

  • Vanda posts 4Q profit Thursday, 19 Feb 2015 | 7:24 AM ET

    WASHINGTON _ Vanda Pharmaceuticals Inc. on Thursday reported fourth-quarter net income of $69.7 million, after reporting a loss in the same period a year earlier. The Washington- based company said it had profit of $1.77 per share. For the year, the company reported net income of $20.2 million, or 55 cents per share, swinging to a profit in the period.

  • Theravance reports 4Q loss Thursday, 19 Feb 2015 | 5:03 AM ET

    SOUTH SAN FRANCISCO, Calif. _ Theravance Inc. on Thursday reported a loss of $15.9 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was also for a loss of 14 cents per share. Theravance shares have risen slightly more than 9 percent since the beginning of the year.

  • LOS ANGELES, Feb 19- As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines. They include BioMarin Pharmaceutical Inc in San Rafael, California, and Sangamo BioSciences Inc in Richmond, California.

  • Regulus reports 4Q loss Wednesday, 18 Feb 2015 | 7:15 PM ET

    SAN DIEGO _ Regulus Therapeutics Inc. on Wednesday reported a loss of $22.2 million in its fourth quarter. The San Diego- based company said it had a loss of 47 cents per share. For the year, the company reported that its loss widened to $56.7 million, or $1.29 per share.

  • Pharmacyclics misses 4Q profit forecasts Wednesday, 18 Feb 2015 | 4:18 PM ET

    SUNNYVALE, Calif. _ Pharmacyclics Inc. on Wednesday reported fourth-quarter earnings of $63.5 million. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 90 cents per share. Pharmacyclics shares have risen 39 percent since the beginning of the year.